The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
about
Recent update in HIV vaccine developmentImmune correlates of vaccine protection against HIV-1 acquisitionSieve analysis in HIV-1 vaccine efficacy trialsCatching HIV 'in the act' with 3D electron microscopyVaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVHIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted InfectionsA Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentH1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Aggregate complexes of HIV-1 induced by multimeric antibodies.A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profilingHIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsA novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infectionComparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination RegimensAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodiesSpecificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesV1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesAnalysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialComparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesDeletion of C7L and K1L genes leads to significantly decreased virulence of recombinant vaccinia virus TianTanVaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesGenetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesPre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine developmentEstimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant.
P2860
Q26766628-ECB8EEE1-98AF-456E-97AD-A69DA9013027Q26778573-743F21C8-0C76-4493-90CB-58886F73942BQ26851376-366A4202-54E9-471F-B8FE-274470086717Q27026806-30F3BE74-B4C6-4558-BB6D-DBE9DC2AFCF8Q27675879-6156A19B-D4D8-4B17-90E4-5DD0FA248A06Q27681527-B3C92C4C-8F7E-4CE7-A57E-4133DAC69CB5Q27687375-5544513F-5FBA-47EE-AE93-CA0CB781742CQ28072213-62584BFE-2F57-49F9-9A4D-516A8379D1D6Q28383579-18D1934D-84C8-4D83-BD36-503A66634090Q30355260-3E5EDAAF-C2D5-4001-820F-4B3093BF3931Q30371297-197EB386-F0E8-4CE9-8DF0-AE4161F2BEC6Q30428633-5C644817-F218-4B5F-A0D6-C034A0D35321Q30648718-039D4763-B032-4774-9283-9EBDD4D67FDBQ33577972-94AE4409-8194-4370-AD45-414E482B49A3Q33645528-50731C81-391B-4C1F-ACB5-2D26A417D727Q33683355-03C1E82B-103C-47E7-B867-4FF67A842D0CQ33712296-EABCF04E-13BC-419C-BA85-729A3DD0BE94Q33742529-15B33360-6299-40CB-A18E-CBA810E034B0Q33743734-FE1CA017-9B60-4F4F-965F-5D0D004984EBQ33813145-B04F870E-206B-44CB-9B6A-BAC673E7CB4DQ33874253-572A3498-7055-49AF-BD0C-705D8FA6E733Q33900395-3BA2549E-DA2A-4E9C-B76E-2F323FBBDB2EQ33915690-D8836663-AE35-41FE-B664-43A47E2AB55AQ33947008-22DF1936-E601-44A8-802B-174066D646BCQ33977866-46D97AAD-47C8-4B61-912E-731588E87660Q34057711-2E51F0D3-C938-44DC-9484-DD4F40C37579Q34057942-FF0AEEBA-6787-42C8-BF3B-9DA77C287773Q34270309-A5AB6D4F-DE16-479D-8A2C-5B6BB9BB406BQ34374835-4EFA16B1-B7DA-4762-A646-D4D6AF2CB15EQ34402934-41877F1A-0ED2-4701-B150-8683B1089CE2Q34414726-70CCD1BB-CA5D-4D1D-9DF9-67EACF33641DQ34562259-7ED87923-C3C5-43E8-BC08-DBF2BB2DDF10Q34616275-A623809B-A8C5-4A43-B7A2-5F0B05C1BA85Q34809121-AC654233-F30B-466D-9491-72EDD06131FDQ34948847-1C5FBC18-E389-4B6A-A7B0-67BC3A33E8B2Q34962907-C5E66296-E58E-4D56-953A-8CE290A85962Q35061529-6EE906BB-9370-405D-AA6A-9E58E25BA363Q35064258-249C82EF-2F08-41D1-96D2-FFD54959E9CAQ35072515-6CDD639C-4575-4ED9-847F-4130BF89163BQ35140508-B6607B6B-8DF9-4E75-94D8-2048EC003C5B
P2860
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@ast
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@en
The Thai Phase III HIV Type 1 Vaccine trial
@nl
type
label
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@ast
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@en
The Thai Phase III HIV Type 1 Vaccine trial
@nl
prefLabel
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@ast
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@en
The Thai Phase III HIV Type 1 Vaccine trial
@nl
P2093
P2860
P50
P921
P356
P1476
The Thai Phase III HIV Type 1 ...... s within the V2 loop of gp120.
@en
P2093
Charla Andrews
Constance Williams
Craig Magaret
Duangnapa Arworn
Erik Billings
Faruk Sinangil
Georgia D Tomaras
Hongmei Gao
Jim Tartaglia
Kelli Greene
P2860
P304
P356
10.1089/AID.2012.0103
P50
P577
2012-10-04T00:00:00Z